Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation

International Journal of Radiation Biology

Volumn 84, Issue 5, 2008, Pages 401-412

  Ara, Gulshan ^a   Watkins, Brynmor A ^b   Zhong, Haihong ^a   Hawthorne, Thomas R ^a   Karkaria, Cyrus E ^a   Sonis, Stephen T ^c   LaRochelle, William J ^a  

^a CURAGEN CORPORATION   (United States)

^b Biomodels   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

FGF 20; Fractionated radiation; Inflammation; Oral mucositis; Velafermin

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR RECEPTOR; VELAFERMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SYRIAN HAMSTER;

ANIMALS; CHEEK; CRICETINAE; EPITHELIUM; FIBROBLAST GROWTH FACTORS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MOUTH MUCOSA; NF-E2-RELATED FACTOR 2; NF-KAPPA B; RADIATION INJURIES; STOMATITIS; TUMOR NECROSIS FACTOR-ALPHA;

CRICETINAE; MESOCRICETUS AURATUS;

EID: 45849139021     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000802007601     Document Type: Article

References (60)

1. Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M, Jeffers M, Dindinger M, Twomlow N, Ghatpande A, LaRochelle WJ, Sonis ST, Lichenstein HS. 2003. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clinical Cancer Research 9:3454-3461.
2. Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. 2005. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. Journal of Clinical Oncology 23:3008-3015.
3. Antin JH, Ferrara JL. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964-2968.
4. Blonder JM. 2001, Topical bioadhesive (biad) antioxidants reduce the severity of experimental radiation-induced oral mucositis. ASCO Annual Meeting Proceedings Abstract 1601.
5. Brach MA, Gruss HJ, Kaisho T, Asano Y, Hirano T, Herrmann F. 1993. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappa B. Journal Biological Chemistry 268:8466-8472.
6. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. 1991. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. Journal of Clinical Investigation 88:691-695.
7. Braun S, Hanselmann C, Gassmann MG, Keller U, Born-Berclaz C, Chan K, Kan YW, Werner S. 2002. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Molecular and Cellular Biology 22:5492-5505.
8. Cho SA, Park JH, Seok SH, Juhn JH, Kim SJ, Ji HJ, Choo YS, Park JH. 2006. Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. Experimental and Toxicologic Pathology 57:321-328.
9. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA. 2003. Transcription factors activated inmammalian cells after clinically relevant doses of ionizing radiation. Oncogene 22:5813-5827.
10. Dorr W. 2002. Acute radiation effects in normal tissues-translational aspects of biological research. Frontiers of Radiation Therapy and Oncology 37:1-8.
11. Dorr W, Bassler S, Reichel S, Spekl K. 2005a. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): Experimental studies in mice. International Journal of Radiation Oncology Biology Physics 62:881-887.
12. Dorr W, Hamilton CS, Boyd T, Reed B, Denham JW. 2002a. Radiation-induced changes in cellularity and proliferation in human oral mucosa. International Journal of Radiation Oncology Biology Physics 52:911-917.
13. Dorr W, Heider K, Spekl K. 2005b. Reduction of oral mucositis by palifermin (rHuKGF): Dose-effect of rHuKGF. International Journal of Radiation Biology 81:557-565.
14. Dorr W, Noack R, Spekl K, Farrell CL. 2001. Modification of oral mucositis by keratinocyte growth factor: Single radiation exposure. International Journal of Radiation Biology 77:341-347.
15. Dorr W, Reichel S, Spekl K. 2005c. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiotherapy and Oncology 75:99-105.
16. Dorr W, Spekl K, Farrell CL. 2002b. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. International Journal of Radiation Oncology Biology Physics 54:245-251.
17. Dorr W, Spekl K, Farrell CL. 2002c. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Proliferation 35(S1):86-92.
18. Egan LJ, Eckmann L, Greten FR, Chae S, Li ZW, Myhre GM, Robine S, Karin M, Kagnoff MF. 2004. IkappaB-kinase-beta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proceedings of the National Academy of Sciences, USA 101:2452-2457.
19. Elting LS, Shih YC, Stiff PJ, Bensinger W, Cantor SB, Cooksley C, Spielberger R, Emmanoulides C. 2007. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: Analysis of phase 3 trial results. Biology of Blood and Marrow Transplantion 13:806-813.
20. Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, Senzer NN, Lockhart PB, Gallagher MJ, Peterson DE, Leveque FG. 2001. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92:875-885.
21. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller SC, Giles FJ, Wierda W, Kwari M, Kantarjian HM. 2006. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45-51.
22. Hofmeister CC, Stiff PJ. 2005. Mucosal protection by cytokines. Current Hematology Reports 4:446-453.
23. Hwang D, Popat R, Bragdon C, O'Donnell KE, Sonis ST. 2005. Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 100:321-329.
24. Itoh N, Ornitz DM. 2004. Evolution of the Fgf and Fgfr gene families. Trends in Genetics 20:563-569.
25. Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL, Sylander ED, Rittman B, Bendele A, Sartor RB, Lichenstein HS. 2002. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 123:1151-1162.
26. Jeffers M, Shimkets R, Prayaga S, Boldog F, Yang M, Burgess C, Fernandes E, Rittman B, Shimkets J, LaRochelle WJ, Lichenstein HS. 2001. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Research 61:3131-3138.
27. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE. 2007. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820-831.
28. Kim JH, Chu F, Lakshmi V, Houde R. 1985. A clinical study of benzydamine for the treatment of radiotherapy-induced mucositis of the oropharynx. International Journal of Tissue Reactions 7:215-218.
29. Knox JJ, Puodziunas AL, Feld R. 2000. Chemotherapy-induced oral mucositis: Prevention and management. Drugs and Aging 17:257-267.
30. Koukourakis MI. 2002. Amifostine in clinical oncology: Current use and future applications. Anticancer Drugs 13:181-209.
31. Lee JM, Johnson JA. 2004. An important role of Nrf2-ARE pathway in the cellular defense mechanism. Journal of Biochemistry and Molecular Biology 37:139-143.
32. Leitao RF, Ribeiro RA, Lira AM, Silva LR, Bellaguarda EA, Macedo FD, Sousa RB, Brito GA. 2008. Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster. Cancer Chemotherapy Pharmacology 61:215-222.
33. Lima V, Brito GA, Cunha Q, Reboucas CG, Falcao BA, Augusto RF, Souza ML, Leitao BT, Ribeiro RA. 2005. Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. European Journal of Oral Sciences 113:210-217.
34. Logan RM, Gibson RJ, Sonis ST, Keefe DM. 2007a. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncology 43:395-401.
35. Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, Keefe DM. 2007b. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews 33:448-460.
36. Maclachlan T, Narayanan B, Gerlach VL, Smithson G, Gerwien RW, Folkerts O, Fey EG, Watkins B, Seed T, Alvarez E. 2005. Human fibroblast growth factor 20 (FGF-20; CG53135-05): A novel cytoprotectant with radioprotective potential. International Journal of Radiation Biology 81:567-579.
37. Peterson DE. 1999. Research advances in oral mucositis. Current Opinion in Oncology 11:261-266.
38. Plevova P. 1999. Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: A review. Oral Oncology 35:453-470.
39. Powers CJ, McLeskey SW, Wellstein A. 2000. Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer 7:165-197.
40. Redding SW. 2005. Cancer therapy-related oral mucositis. Journal of Dental Education 69:919-929.
41. Schmid RM, Adler G. 2000. NF-kappaB/rel/IkappaB: Implications in gastrointestinal diseases. Gastroenterology 118:1208-1228.
42. Silverman S Jr. 2007. Diagnosis and management of oral mucositis. Journal of Supportive Oncology 5:13-21.
43. Sonis ST. 2002. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Critical Reviews in Oral Biology and Medicine 13:380-389.
44. Sonis ST. 2004. Oral mucositis in cancer therapy. Journal of Supportive Oncology 2:3-8.
45. Sonis ST. 2005. Mechanism of action of benzydamine in the treatment of oral mucositis. ASCO Annual Meeting Proceedings Abstract 8084.
46. Sonis ST, Elting LS, Keefe DM, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. 2004a. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995-2025.
47. Sonis ST, Fey EG. 2002. Oral complications of cancer therapy. Oncology (Williston Park) 16:680-686,691-692,695.
48. Sonis ST, O'Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB. 2004b. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncology 40:170-176.
49. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M. 2001. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. Journal Clinical Oncology 19:2201-2205.
50. Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, Login G,Ymamkawa M, Moses G, Bouchard P, Hayes LL, Bedrosian C, Dorner AJ. 2000. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncology 36:373-381.
51. Sonis ST, Scherer J, Phelan S, Lucey CA, Barron JE, O'Donnell KE, Brennan RJ, Pan H, Busse P, Haley JD. 2002. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Proliferation 35(S1):93-102.
52. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C. 2004. Palifermin for oral mucositis after intensive therapy for hematologic cancers. New England Journal of Medicine 351:2590-2598.
53. Stiff PJ, Emmanouilides C, Bensinger W, Gentile T, Blazar B, Shea TC, Lu J, Isitt J, Cesano A, Spielberger R. 2006. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. Journal of Clinical Oncology 24:5186-5193.
54. Stokman MA, Wachters FM, Koopmans P, Burgerhof JGM, Groen HJM, Spijkervet FKL, Uges DRA, Hospers GAP. 2004. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research 24:3263-3267.
55. Szebenyi G, Fallon JF. 1999. Fibroblast growth factors as multifunctional signaling factors. International Review Cytology 185:45-106.
56. Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, Takahi K, Nakase T, Kaneda Y, Yoshikawa H, Ochi T. 2000. Transcription factor decoy for NFkB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (Oxford) 39:749-757.
57. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD. 2003. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiotherapy and Oncology 66:253-262.
58. Vera-Llonch M, Oster G, Hagiwara M, Sonis ST. 2006. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106:329-336.
59. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, Fraser CJ, Scarffe JH. 2000. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. British Journal Haematology 110:292-299.
60. Yeoh ASJ, Bowen JM, Gibson RJ, Keefe DMK. 2005. Nuclear factor kB (NFκB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. International Journal Radiation Oncology Biology Physics 63:1295-1303.